Company
Description
Headquartered in Hong Kong, Editact Therapeutics is dedicated to advancing genome editing technologies and human health. We are pioneering novel, first-in-class “one-for-many” genome editing solutions to familial diseases. Our first drug lead aims to target and treat Familial Alzheimer’s disease (FAD). Editact is committed to addressing unmet medical needs through genome editing, thus offering a new lease on life for patients with inherited and otherwise incurable diseases.
